Company Profile For Amylin Pharmaceuticals, Inc.

Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. As of December 31, 2008, the Company was marketing two medicines to treat diabetes: BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. In addition to its marketed products, the Company is working with Eli Lilly and Company (Lilly) and Alkermes, Inc. (Alkermes) to develop exenatide once weekly. The Company maintains a discovery research program focused on peptide and protein therapeutics.

BRIEF: For the nine months ended 30 September 2009, Amylin Pharmaceuticals, Inc. revenues decreased 4% to $614.3M. Net loss decreased 37% to $136M. Revenues reflect lower revenues under collaborative agreements. Lower loss reflects a decrease in cost of goods sold, lower selling, general & administrative costs due to decrease in cost structure and decreased research & development expenses due decrease in obesity development programs.